06821.HK
Asymchem Laboratories (Tianjin) Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 103.90
−1.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.4B | 6.7B | 5.8B | 7.8B | 10.3B |
| Cost of Revenue | 4.4B | 3.9B | 3.3B | 3.8B | 5.4B |
| Gross Profit | 3.0B | 2.8B | 2.5B | 4.0B | 4.9B |
| Operating Expenses | |||||
| R&D Expense | 509.6M | 593.3M | 614.5M | 707.9M | 708.9M |
| SG&A Expense | 369.3M | 260.9M | 331.7M | 358.2M | 385.6M |
| General & Admin Expense | 280.6M | 194.1M | 244.0M | 293.9M | 235.4M |
| Selling & Marketing Expense | 88.7M | 66.8M | 87.6M | 64.3M | 150.2M |
| Other Expenses | 745.0M | 692.6M | 434.0M | 366.5M | 3.5M |
| Total Operating Expenses | 1.6B | 1.5B | 1.4B | 1.4B | 1.7B |
| Cost and Expenses | 6.1B | 5.4B | 4.7B | 5.3B | 7.1B |
| Operating Income (EBIT) | 1.3B | 1.3B | 1.1B | 2.6B | 3.7B |
| Non-Operating | |||||
| Interest Income | 164.8M | 203.0M | 210.4M | 160.1M | 76.6M |
| Interest Expense | 14.4M | 12.8M | 9.5M | 5.9M | 10.5M |
| Net Interest Income | 150.4M | 190.2M | 200.3M | 153.8M | 65.4M |
| Other Non-Op Income/Expense | (60.6K) | 32.3M | (6.3M) | (13.7M) | (5.8M) |
| Non-Operating Income (excl Interest) | 126.0M | (45.0M) | (3.2M) | 7.8M | (4.7M) |
| EBT (Pre-Tax Income) | 1.3B | 1.3B | 1.1B | 2.6B | 3.7B |
| Income Tax Expense | 145.9M | 159.7M | 136.6M | 306.3M | 430.3M |
| Bottom Line | |||||
| Net Income | 1.2B | 1.1B | 949.0M | 2.3B | 3.3B |
| Earnings from Cont. Ops | 1.2B | 1.1B | 935.8M | 2.3B | 3.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.2B | 1.1B | 949.0M | 2.3B | 3.3B |
| Per Share | |||||
| Basic EPS | HK$3.31 | HK$3.19 | HK$2.69 | HK$6.26 | HK$9.02 |
| Diluted EPS | HK$3.31 | HK$3.19 | HK$2.69 | HK$6.26 | HK$9.00 |
| Revenue Per Share | HK$20.44 | HK$18.80 | HK$16.36 | HK$21.59 | HK$28.02 |
| Shares | |||||
| Basic Shares Outstanding | 361.9M | 354.9M | 354.9M | 362.4M | 366.0M |
| Diluted Shares Outstanding | 361.9M | 354.9M | 354.9M | 362.4M | 366.8M |
| Profitability Metrics | |||||
| EBITDA | 1.6B | 1.8B | 1.6B | 3.0B | 4.1B |
| D&A | 313.0M | 550.9M | 502.5M | 463.9M | 341.7M |
| EBIT | 1.3B | 1.3B | 1.1B | 2.6B | 3.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026